Insulin Icodec and Semaglutide in One Pen in Brazil: What ANVISA Registration Changes

A once-weekly pen that combines insulin icodec and semaglutide is getting attention in Brazil, and it's easy to see why. Many adults with type 2 diabetes already take a basal insulin and a GLP-1 medicine, often as two separate shots. Putting both into one device could mean one injection a week instead of two. Here's what the pen contains, what ANVISA registration does and doesn't change, and what to check before you talk with your doctor.

What the pen actually contains

The pen holds two medicines. Insulin icodec is a basal insulin taken once a week. Semaglutide is a GLP-1 receptor agonist, also given once a week. Both sit in one device at a fixed ratio, so each dose step delivers the two components in a set proportion. The exact unit ratio and dose-step rules are written in the Bula, the official leaflet for the product. Check them there rather than relying on any summary, this one included.

The reasoning behind pairing them is straightforward. Basal insulin lowers blood glucose overnight and between meals. Semaglutide works through a different pathway, acting on GLP-1 receptors. Combining them in one pen can simplify a regimen that many people already follow with two products.

What ANVISA registration means, and what it doesn't

ANVISA, Brazil's health regulator, grants registration as an authorization to sell a medicine in the country. Before approving a product, the agency reviews efficacy, safety, and quality data. That's a serious review, but it's only one step.

Three questions get mixed up all the time. Is the product registered? Is it covered by SUS or a private plan? Is it on pharmacy shelves right now? Each question has its own answer and its own source. Registration answers only the first. Coverage depends on SUS incorporation decisions and your insurer's rules. Availability depends on supply and distribution.

CONITEC evaluates whether technologies should be incorporated into SUS. Look up its current status on the CONITEC website instead of assuming an outcome. Prices, when published, come from CMED, the chamber that regulates maximum prices for medicines in Brazil.

Who the pen is for, and who should be careful

The Bula sets the indication, and the wording matters. The combination was studied in adults with type 2 diabetes, but indications can differ between Brazil, Europe, and the United States. Read the Brazilian text itself. Type 1 diabetes is not the target population for this product, but confirm that against the label.

Because the pen contains semaglutide, the warnings for that drug class apply. The main ones concern a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, and pregnancy. Read the contraindication and warning sections word for word in the Bula.

People already using a basal insulin with a GLP-1 medicine may be the most natural candidates for a switch, since the pen mirrors that regimen in one device. Still, that's a clinical judgment. Your prescribing doctor weighs your history, glucose data, and goals.

What the clinical trials looked at

The combination was tested in the COMBINE phase 3 program, in adults with type 2 diabetes. Each study has its own comparators, population, and duration. I won't quote numbers from memory. The exact HbA1c changes, weight changes, and hypoglycemia rates are in the published papers, and you can find them by searching PubMed for the COMBINE studies.

What does a hypoglycemia comparison tell you? It shows how often low blood sugar episodes happened in each group. Fewer episodes can matter a lot if you've had lows before. But the rates only make sense alongside the study population, the trial length, and how episodes were defined. Trials run for a fixed period, so they can't say much about years of use.

Keep the limits in view. Trials exclude certain groups, so check each paper's eligibility criteria. Read the limitations sections too, not just the abstract.

Switching and daily use

Moving from separate basal insulin and GLP-1 injections, or from a different basal insulin, is a clinical decision. The Bula describes how transitions should be handled, including dose adjustments. Follow that text and your doctor's plan. Don't change your dose on your own, even if the new pen looks simpler.

Two side effect areas matter most. Semaglutide products are linked to gastrointestinal effects, which the Bula lists among adverse reactions. Insulin carries a risk of hypoglycemia, especially when doses change. Ask your doctor how often to check your blood glucose and what to do if readings run low.

Storage and handling count too. The storage section of the Bula covers refrigeration before first use and limits once the pen is in use. Use a new needle for each injection and handle the device exactly as the leaflet describes. If you want a plain-language walkthrough of how these regimens compare, the team at OzemNews keeps a running guide.

Access in Brazil: cost, prescriptions, and buying safely

Access usually comes through SUS, a private health plan, or paying out of pocket. Under SUS, check whether the product has been incorporated and where it's dispensed. With a private plan, check the coverage list and whether prior authorization applies. Out of pocket, look up the price in the CMED table rather than trusting a pharmacy sign or a forum post.

Prescription requirements for GLP-1 and insulin products should be checked against current ANVISA rules, because they can change. Ask your doctor and pharmacist what applies when you buy.

Before you buy, run a quick check:

• Confirm the ANVISA registration number on the box matches the Bula in the ANVISA Bulário.
• Buy only from a licensed pharmacy with a physical address.
• Make sure you hold a valid prescription from your doctor.

Counterfeit pens are a real concern, so verify the box and leaflet before you use anything. Our coverage at OzemNews has tracked this kind of counterfeit risk for a while, so it's worth reading before you buy.

Questions for your doctor and what to watch next

Bring a short list to your endocrinologist. Ask whether the combination suits your current regimen. Ask whether your history of low blood sugar changes the picture. Ask how your kidney function affects dosing and monitoring. Ask which cost options are realistic for you, and what happens if the fixed ratio doesn't match the dose you need.

Three milestones are worth tracking. The first is CONITEC's decision on SUS incorporation. The second is CMED pricing, once it's listed. The third is real-world data from Brazilian users, which can show how the product performs outside trials.

Registration widens your options, but it doesn't replace individual medical decisions. Approval doesn't make a product right for everyone. For updates as these milestones arrive, the OzemNews newsletter is where we flag changes as they happen.

FAQ

Is the insulin icodec and semaglutide pen approved in Brazil?

Registration is granted by ANVISA. Check the number on the box against the Bula in the ANVISA Bulário. Registration alone doesn't guarantee SUS coverage, a private plan listing, or pharmacy stock.

Can I use this pen if I have type 1 diabetes?

The combination was studied in adults with type 2 diabetes. Confirm the indication in the Brazilian Bula and talk with your doctor before considering it.

Who should avoid semaglutide-containing products?

The Bula lists contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2. A history of pancreatitis or pregnancy calls for careful review. Discuss the exact warnings with your doctor.

How often do I inject it?

The pen is designed for one injection a week. The exact schedule and any dose steps are set out in the Bula, so follow that and your doctor's instructions.

Sources

• ANVISA - Bulário Eletrônico (consulta de bulas)
• ANVISA - Agência Nacional de Vigilância Sanitária
• CONITEC - Comissão Nacional de Incorporação de Tecnologias no SUS
• CMED - Câmara de Regulação do Mercado de Medicamentos
• Ministério da Saúde
• PubMed - busca por estudos do programa COMBINE (insulin icodec e semaglutide)